Dr. S Dravida is the Founder CEO of Tran-Scale Biologics Pvt. Ltd (www.tran-scell.com), an Adult Stem Cell Company at Hyderabad, India. She is an entrepreneurial technocrat of global standing having worked in the USA, Canada, and India in the domains of stem cell research, training and commercialization. She has a unique blend of experiences & skills of wet lab, product development to managing the business. Under her stewardship, Tran-Scale Biologics, a knowledge-driven technology intensive entity has evolved from its inception in 2009 as a donor specific stem cell repository to a fully integrated biotechnology enterprise encompassing a well-balanced business portfolio of stem cell banking and processing services with research towards 7 stem cell products in pipeline addressing Oncology, Auto-immunity, and Bone/Cartilage anomalies. Her efforts are diversified in the stem cell applications enterprise encircling both the therapeutic and non-therapeutic segments with a clear progressive growth path set for Tran-Schell's homegrown technologies and intellectual properties.
She is a biologist by education with clinical informatics research experience having associated professionally with the University of North Carolina, USA, Ottawa Health Research Institute, Canada. S Dravida has peer reviewed publications and patents to her credit and was nominated for women in leadership award in 2011 in science and recipient of 2012, small business industrial research award to develop dental stem cell treatment products/processes in implantology. In 2013, she obtained the research grant from parent’s society to develop stem cell treatment protocols for treating muscular dystrophies. She has the special interest and has been working on both pluripotent and cancer stem cell based platforms for drug screening in India since 2014 onwards.
One-size-fits-all approach to treat cancers is outdated in the modern medicine while the shift is towards personalized medicine strategy that focuses on the discovery and development of small molecules that would target the resident tumor specific stem cells killing them. These technological characteristics are increasingly being explored for treating the death sentence called cancer with understanding the abnormal biology, genetics of cancer cells, cancer genome sequencing including functional and phenotypic screens. In this talk, the speaker would provide an overview of latest approaches to the fascination towards small molecules as cancer drugs, highlighting success stories and global trend. The focus of the talk would revolve around: Targets, Types & Examples of targeted therapy, The mechanisms of action and toxicities of targeted therapies differing from those of traditional chemotherapy, Small molecule inhibitors for cancer treatment, FDA approved small molecules to treat cancers, nature inspired hybrid small molecules being explored for targeted killing of cancer cells.